Open AccessHow could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Author(s) -
Urvi M. Parikh,
John W. Mellors
Publication year - 2022
Publication title -
current opinion in hiv and aids
Language(s) - English
Resource type - Journals
eISSN - 1746-6318
pISSN - 1746-630X
DOI - 10.1097/coh.0000000000000746
Subject(s) - pre exposure prophylaxis , emtricitabine , medicine , hiv drug resistance , drug resistance , tenofovir , clinical trial , human immunodeficiency virus (hiv) , drug , microbicide , virology , pharmacology , antiretroviral therapy , viral load , men who have sex with men , biology , syphilis , microbiology and biotechnology
To review current laboratory and clinical data on the frequency and relative risk of drug resistance and range of mutations selected from approved and investigational antiretroviral agents used for preexposure prophylaxis (PrEP) of HIV-1 infection, including tenofovir disproxil fumarate (TDF)-based oral PrEP, dapivirine ring, injectable cabotegravir (CAB), islatravir, lenacapavir and broadly neutralizing antibodies (bNAbs).